Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
HDFC Asset Management Company: A big draw

6h premium.thehindubusinessline
Strong investor inflows, growing awareness and an upbeat capital market have augured well for the mutual fund industry in the last three to four years. HDFC Asset Management Company — consistently among the top two players in terms of assets under management (AUM) in the last few years — has been able to capitalise on the good fortunes of the industry, registering strong growth in revenues and profit.
HDFC 500010 HDFC

0
HDFC AMC said to have priced its IPO lower than market expectation

2018-07-20 livemint
Mumbai: HDFC Asset Management Co. Ltd, which is launching its initial public offering (IPO) on 25 July, has priced its shares at ₹1,095-1,100 apiece, valuing the asset manager at ₹23,319 crore. The country’s second largest asset management company is a joint venture of mortgage lender Housing Development Finance Corp. Ltd (HDFC) and Standard Life Investments Ltd.
SLFPF SL HDFC 500010 HDFC SLFPY

0
'Huge growth potential for mutual fund industry in India'

2018-07-19 thehindubusinessline
The country’s mutual fund industry has a huge growth potential as Indian households’ savings amount to Rs 20-30 lakh crore, top official of an asset management company said today.
SLFPF SL HDFC 500010 HDFC SLFPY

0
Indian shares flat ahead of Friday's no-trust motion

2018-07-19 thehindubusinessline
Shares of various companies were muted on Thursday with losses in heavyweights such as Tata Consultancy Services Ltd offsetting gains in consumer stocks including Hindustan Unilever Ltd, a day ahead of a no-confidence motion against the government.
532540 500696 HINDUNILVR TCS HDFC HEXAWARE 532129 TTNQY 500010 HDFC MNDQY

0
HDFC mutual fund arm to launch its ₹2,800 crore initial share sale next week

2018-07-18 livemint
Mumbai: HDFC Asset Management Co. Ltd, the second largest mutual fund company in India, will launch its ₹2,800 crore initial public offering (IPO) on 25 July, the company said on Wednesday.
SLFPF SL HDFC 500010 HDFC SLFPY

0
Deepak Parekh wants to make HDFC Ergo larger before taking it public

2018-07-18 moneycontrol
The wait just got longer for investors eagerly looking forward to the listing of Housing Development Finance Corp's Ergo General Insurance Company.
HDFC 500010 HDFC

1
HDFC shares hit record high ahead of Rs 2,800cr AMC IPO next week

2018-07-18 moneycontrol
Housing Development Finance Corporation share price gained 1.2 percent intraday on Wednesday after its subsidiary HDFC Asset Management Company decided to open the initial public offering for subscription next week.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

1
HDFC Bank stock gains 2% to hit all-time high after raising funds from parent firm

2018-07-18 moneycontrol
HDFC Bank share price rallied 2 percent intraday to hit a fresh record high of Rs 2,219 on Wednesday after raising of funds from its parent firm.
HDB 500180 HDFCBANK HDFC 500010 HDFC

1
HDFC Bank raises Rs8,500 crore by issuing equity to parent HDFC

2018-07-17 livemint
New Delhi: HDFC Bank on Tuesday said it has raised Rs8,500 crore by issuing over 3.9 crore shares on preferential basis to its parent HDFC Ltd.
HDB 500180 HDFCBANK HDFC 500010 HDFC

1
HDFC Bank raises Rs 8,500 cr by issuing equity to parent HDFC

2018-07-17 moneycontrol
HDFC Bank today said it has raised Rs 8,500 crore by issuing over 3.9 crore shares on preferential basis to its parent HDFC Ltd.
HDB 500180 HDFCBANK HDFC 500010 HDFC

1
HDFC AMC sets IPO price band at Rs 1,095-1,100

2018-07-17 thehindubusinessline
HDFC Asset Management Company, the country’s second largest mutual fund firm, has fixed a price band of Rs 1,095-1,100 per share for its initial public offering, through which it is estimated to garner Rs 2,800 crore.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

0
Building material retailer Shankara plans to raise ₹300 crore through QIP

2018-07-09 livemint
Mumbai: Shankara Building Products Ltd, an organized retailer of home improvement and building material, has appointed an investment bank to raise up to ₹300 crore through a qualified institutional placement (QIP), said two people aware of the development.
523405 OBZIY OBEROIRLTY 533273 IDEA ICLQY HDFC 532822 500010 HDFC JMFINANCIL

0
Risky lending practices, possible job losses may cause home loan defaults: HDFC

2018-07-05 moneycontrol
Aggressive lending practices and possible job losses may restrict repayment capacity of home loan borrowers, according to country’s largest home financier HDFC.
535789 IBULHSGFIN DHFL 511072 IDKQY HDFC 500010 HDFC

0
In letter to shareholders, Deepak Parekh details succession plans at HDFC

2018-07-05 moneycontrol
Housing Development Finance Corporation (HDFC) Chairman Deepak Parekh said in his annual letter to shareholders that a smooth transition within the group will be his top-priority, according to a Mint report.
HDFC 500010 HDFC

0
ICICI Bank grows home loans to Rs 1.5 lakh cr; average age of borrowers at 35-40 years

2018-07-04 moneycontrol
ICICI Bank will focus on rising affordability of Indians and expand to 500 new locations to grow its mortgage business to Rs 2 lakh crore by March-end 2020.
535789 IBULHSGFIN ICICIBANK 532174 IBN IDKQY HDFC 500010 HDFC SBAZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...